Montmorillonite-PLGA nanocomposites as an oral extended drug delivery vehicle for venlafaxine hydrochloride

• Combination of Mt with PLGA for VF is being reported for the first time.
• Effect of Mt on encapsulation efficiency and in vitro release of VF was studied.
• Presence of Mt reduces the burst effect and provides better control of VF release.

The objective of the present study is to develop montmorillonite (Mt) based PLGA nanocomposites for oral and controlled release carrier for an antidepressant drug, venlafaxine hydrochloride (VF). VF loaded CPN were prepared using double emulsion solvent evaporation technique. The synthesized CPN were compared with respect to morphology, particle size, physical status of VF and Mt and in vitro drug release to the corresponding biodegradable PLGA nanoparticles. Mt based VF-PLGA nanocomposites suggest the possibility of designing the oral and controlled release formulations to minimize the drug administration frequency and the occurrence of side effect thereby increasing the effectiveness of drug and hence improving patient compliance.

Figure optionsDownload as PowerPoint slide